Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (486)	2/1/2000 2:55:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 1834

Good news. I just looked at the prospectus for SQNM, and the current market cap is about $1.9 billion. Since we know that this is a rational market, that must mean that NBIX will be selling for $400 before today's close. Sigh.

To: Biotech Jim who wrote (486)	2/1/2000 8:39:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 1834

BJ, Yes, GnRH is from NNI. Company in their milestone for "00 mentioned GnRH antagonist drug candidate (endometriosis and prostate cancer), and IND in "01 . However, giving NBIX resource (man-power, $$$, lab space,...) and programs priority my view is that someone will be interested for this program and release NBIX from further expense. CRF and MC receptors is more than sufficient to make busy everyone at NBIX , so let someone continue from where they are now. I do think that this program may generate nice opportunity for mid-size player in pharma market. Abarelix is peptide. BTW, nice to see that I am not the only one who see value in NNI patents on MC receptors.(Thanks Rick) Miljenko